Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$271.19−0.54 (-0.20%)
Close on Nov 17, 2026Market cap $16.81BP/E 22.3Yield –
Ascendis Pharma A/S operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ascendis Pharma A/S's operating cash flow for the twelve months ending Jun 30, 2026 was €349.51M. For fiscal 2025 it was €53.90M. The highest annual figure on record is €53.90M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €53.90M | – |
| FY2024 | Dec 31, 2024 | -€306.20M | – |
| FY2023 | Dec 31, 2023 | -€467.36M | – |
| FY2022 | Dec 31, 2022 | -€495.70M | – |
| FY2021 | Dec 31, 2021 | -€417.65M | – |
| FY2020 | Dec 31, 2020 | -€271.55M | – |
| FY2019 | Dec 31, 2019 | -€175.94M | – |
| FY2018 | Dec 31, 2018 | -€138.80M | – |
| FY2017 | Dec 31, 2017 | -€95.10M | – |
| FY2016 | Dec 31, 2016 | -€60.18M | – |
| FY2015 | Dec 31, 2015 | -€43.47M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €281.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -€7.72M | – |
| Q4 FY2025 | Dec 31, 2025 | €73.40M | – |
| Q3 FY2025 | Sep 30, 2025 | €2.15M | – |
| Q2 FY2025 | Jun 30, 2025 | -€7.34M | – |
| Q1 FY2025 | Mar 31, 2025 | -€14.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -€87.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -€56.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -€61.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -€101.58M | – |
| Q4 FY2023 | Dec 31, 2023 | -€42.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -€124.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -€153.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -€147.04M | – |
| Q4 FY2022 | Dec 31, 2022 | -€141.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -€98.83M | – |
| Q2 FY2022 | Jun 30, 2022 | -€124.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -€130.79M | – |
| Q4 FY2021 | Dec 31, 2021 | -€123.31M | – |
| Q3 FY2021 | Sep 30, 2021 | -€97.52M | – |
| Q2 FY2021 | Jun 30, 2021 | -€115.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -€81.62M | – |
| Q4 FY2020 | Dec 31, 2020 | -€90.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -€57.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -€56.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -€66.79M | – |
| Q4 FY2019 | Dec 31, 2019 | -€49.24M | – |
| Q3 FY2019 | Sep 30, 2019 | -€59.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -€5.89M | – |
| Q1 FY2019 | Mar 31, 2019 | -€60.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -€35.56M | – |
| Q3 FY2018 | Sep 30, 2018 | -€46.39M | – |
| Q2 FY2018 | Jun 30, 2018 | -€20.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -€36.74M | – |
| Q4 FY2017 | Dec 31, 2017 | -€24.16M | – |
| Q3 FY2017 | Sep 30, 2017 | -€25.78M | – |
| Q2 FY2017 | Jun 30, 2017 | -€23.92M | – |
| Q1 FY2017 | Mar 31, 2017 | -€21.25M | – |
See a number that looks wrong?